Hydrocortisone autoinjector - Crossject
Alternative Names: Needleless hydrocortisone autoinjector; ZENEO - Crossect; ZENEO® Hydrocortisone Autoinjector; ZENEO® needleless deviceLatest Information Update: 19 Apr 2024
At a glance
- Originator Crossject
- Class Anti-inflammatories; Antiallergics; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Adrenal insufficiency
Most Recent Events
- 19 Apr 2024 Eton Pharmaceuticals announces intention to submit NDA to US FDA for Adrenal insufficiency in 2024
- 31 Mar 2023 Hydrocortisone autoinjector - Crossject receives Orphan Drug status for Adrenal insufficiency in USA
- 03 Nov 2022 Clinical trials in Adrenal insufficiency in USA (unspecified route) as of November 2022